company background image
MITO logo

Stealth BioTherapeutics NasdaqGM:MITO Stock Report

Last Price

US$0.32

Market Cap

US$23.5m

7D

-0.1%

1Y

-68.0%

Updated

16 Nov, 2022

Data

Company Financials +

Stealth BioTherapeutics Corp

NasdaqGM:MITO Stock Report

Market Cap: US$23.5m

This company has been acquired

The company may no longer be operating, as it has been acquired. Find out why through their latest events.

MITO Stock Overview

Stealth BioTherapeutics Corp, a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of therapies for diseases involving mitochondrial dysfunction.

MITO fundamental analysis
Snowflake Score
Valuation2/6
Future Growth0/6
Past Performance0/6
Financial Health0/6
Dividends0/6

Stealth BioTherapeutics Corp Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Stealth BioTherapeutics
Historical stock prices
Current Share PriceUS$0.32
52 Week HighUS$1.03
52 Week LowUS$0.16
Beta1.46
1 Month Change1.75%
3 Month Change3.76%
1 Year Change-68.00%
3 Year Change-95.86%
5 Year Changen/a
Change since IPO-97.31%

Recent News & Updates

Recent updates

Stealth Biotherapeutics chief financial officer Robert Weiskopf leaves company

Sep 30

Stealth BioTherapeutics shares pop ~20% premarket after co agrees to go private

Aug 01

Stealth BioTherapeutics: A Net-Net Biopharma Going Private

Jul 26

Stealth BioTherapeutics receives Nasdaq non-compliance receipt

Jul 11

Stealth Biotherapeutics shares soar on EMA orphan drug status for elamipretide

Jun 01

Stealth BioTherapeutics skyrockets on data for elamipretide studies

May 06

FDA accepts Stealth Bio's Pre-NDA meeting request for elamipretide

Jan 06

Reflecting on Stealth BioTherapeutics' (NASDAQ:MITO) Share Price Returns Over The Last Year

Dec 31
Reflecting on Stealth BioTherapeutics' (NASDAQ:MITO) Share Price Returns Over The Last Year

Stealth Bio launches $3.2M registered direct offering

Nov 20

Shareholder Returns

MITOUS BiotechsUS Market
7D-0.1%0.2%1.3%
1Y-68.0%10.2%29.8%

Return vs Industry: MITO underperformed the US Biotechs industry which returned -14.2% over the past year.

Return vs Market: MITO underperformed the US Market which returned -21.5% over the past year.

Price Volatility

Is MITO's price volatile compared to industry and market?
MITO volatility
MITO Average Weekly Movement1.5%
Biotechs Industry Average Movement11.6%
Market Average Movement6.0%
10% most volatile stocks in US Market16.8%
10% least volatile stocks in US Market3.0%

Stable Share Price: MITO has not had significant price volatility in the past 3 months.

Volatility Over Time: MITO's weekly volatility has decreased from 14% to 2% over the past year.

About the Company

FoundedEmployeesCEOWebsite
200638Reenie McCarthyhttps://www.stealthbt.com

Stealth BioTherapeutics Corp, a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of therapies for diseases involving mitochondrial dysfunction. Its lead product candidate is Elamipretide that is in phase 3 clinical trial to treat barth syndrome, phase 2/3 clinical trial for the treatment of duchenne cardiomyopathy, phase 2a clinical trial to treat friedreich’s ataxia, phase 2 clinical trial for the treatment of dry age-related macular degeneration, phase 2 clinical trial to treat leber’s hereditary optic neuropathy, and phase 3 clinical trial for the treatment of replisome myopathies. The company’s product candidates also include SBT-20 to treat complications of diabetes, renal diseases, ocular diseases, neurodegenerative, Parkinson’s, Alzheimer’s, Huntington’s, and ALS diseases; SBT-550 for rare neurological indications; and SBT-272, a peptidomimetic that targets the mitochondria and stabilizing mitochondrial function under conditions of oxidative stress, as well as SBT 550.

Stealth BioTherapeutics Corp Fundamentals Summary

How do Stealth BioTherapeutics's earnings and revenue compare to its market cap?
MITO fundamental statistics
Market capUS$23.54m
Earnings (TTM)-US$52.53m
Revenue (TTM)n/a

0.0x

P/S Ratio

-0.4x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
MITO income statement (TTM)
RevenueUS$0
Cost of RevenueUS$0
Gross ProfitUS$0
Other ExpensesUS$52.53m
Earnings-US$52.53m

Last Reported Earnings

Dec 31, 2021

Next Earnings Date

n/a

Earnings per share (EPS)-0.71
Gross Margin0.00%
Net Profit Margin0.00%
Debt/Equity Ratio-30.1%

How did MITO perform over the long term?

See historical performance and comparison
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.